| answer text |
<p>Guidance has been provided to support vaccine trial participants who wished to
be unblinded at a time when they became eligible for an approved COVID-19 vaccine.
This suggests individuals should discuss with the principle investigator at the site
in which the participant was recruited who are best placed to advise on the options
following unblinding.</p><p>In general, participants who only received a placebo would
be recommended to receive the deployed COVID-19 vaccine schedule. Those that received
a full course of an active vaccine, would be advised that further doses of deployed
vaccine were not advisable. Whilst antibody tests were performed in the study, the
advice on further vaccination would be based on the record of the participant's previous
doses in the trial.</p>
|
 |
